OGEN - Latest News
Oragenics, Inc. (OGEN), operates in Healthcare / Biotechnology, trades on AMEX.
Market capitalization stands near $2.7M. Beta to the broader market is 1.26.
The article list below shows the most recent OGEN headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent OGEN Headlines
Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21
globenewswire.com - May 19, 2026
Sarasota, FL, May 19, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutic
ORAGENICS PROVIDES INVESTOR UPDATE
globenewswire.com - May 18, 2026
A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Sarasota, FL, May 18, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) Dear Fellow Sharehold
ORAGENICS PROVIDES INVESTOR UPDATE
globenewswire.com - May 18, 2026
A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Sarasota, FL, May 18, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) Dear Fellow Sharehold
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
globenewswire.com - May 7, 2026
The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sid
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
globenewswire.com - May 7, 2026
The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sid
How News Affects OGEN Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track OGEN's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked OGEN news questions
- What is the latest OGEN news headline?
- The most recent OGEN headline (May 19, 2026) is "Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the OGEN news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What OGEN news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual OGEN options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.